Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Pandha

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Clinical and Experimental Immunology|February 17, 2007
Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell linesH Pandha, A Rigg, J John, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 10, 2015
The tolerability of sunitinib in elderly patients with metastatic renal cancerA Michael, J Coward, A Brown, et al.
Surgical Oncology|May 29, 2002
Advances in prostate cancer immunotherapyE G Havranek, M A Whelan, R Greenhalgh, et al.
Gut|November 21, 1998
Can immunotherapy by gene transfer tip the balance against colorectal cancer?S M Todryk, H Chong, R G Vile, et al.
British Journal of Cancer|June 11, 2009
Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapyM Ismail, S Bokaee, Richard Morgan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 28, 2008
Reovirus: viral therapy for cancer 'as nature intended'C Comins, L Heinemann, K Harrington, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
The role of adenoviral vectors in genetic prodrug activation therapy in prostate cancerJ D Eaton, I A Clarke, H Pandha, et al.
Prostate Cancer and Prostatic Diseases|August 4, 2005
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancerJ Spicer, T Plunkett, N Somaiah, et al.
Clinical and Experimental Immunology|October 23, 2004
The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressorsJ Stebbing, M Bower, B Gazzard, et al.
The Journal of Urology|May 19, 2007
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II studyR Lord, S Nair, A Schache, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Immunology|February 17, 2007
Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell linesH Pandha, A Rigg, J John, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 10, 2015
The tolerability of sunitinib in elderly patients with metastatic renal cancerA Michael, J Coward, A Brown, et al.
Surgical Oncology|May 29, 2002
Advances in prostate cancer immunotherapyE G Havranek, M A Whelan, R Greenhalgh, et al.
Gut|November 21, 1998
Can immunotherapy by gene transfer tip the balance against colorectal cancer?S M Todryk, H Chong, R G Vile, et al.
British Journal of Cancer|June 11, 2009
Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapyM Ismail, S Bokaee, Richard Morgan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 28, 2008
Reovirus: viral therapy for cancer 'as nature intended'C Comins, L Heinemann, K Harrington, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
The role of adenoviral vectors in genetic prodrug activation therapy in prostate cancerJ D Eaton, I A Clarke, H Pandha, et al.
Prostate Cancer and Prostatic Diseases|August 4, 2005
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancerJ Spicer, T Plunkett, N Somaiah, et al.
Clinical and Experimental Immunology|October 23, 2004
The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressorsJ Stebbing, M Bower, B Gazzard, et al.
The Journal of Urology|May 19, 2007
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II studyR Lord, S Nair, A Schache, et al.
Pageof 4